secwatch.observer — SEC 8-K summary
======================================

Issuer:     Benitec Biopharma Inc. (BNTC)
CIK:        0001808898
Form:       8-K
Filed at:   2022-12-08T23:59:59+00:00
Accession:  0001193125-22-301044
Event type: other_material
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Benitec shareholders reject preferred stock authorization at 2022 annual meeting
--------------------------------------------------------------------------------

- Proposal 5 to authorize 5M shares of preferred stock failed; all other proposals passed.
- Directors Jerel Banks and Megan Boston elected with ~98% of votes cast (excluding broker non-votes).
- Shareholders approved increase in authorized common stock, reverse stock split, and advisory say-on-pay.
- Ratification of independent auditor (BDO USA) received 18.7M for, 137k against, 118k abstain.
- Broker non-votes on four proposals totaled 5.2M shares out of 19.0M present at the meeting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1808898/000119312522301044/0001193125-22-301044-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1808898/000119312522301044/d352118d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-301044

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer